Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials
- PMID: 16421421
- DOI: 10.1200/JCO.2005.03.6392
Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials
Abstract
Purpose: Systemic treatments for advanced non-small-cell lung cancer have low efficacy and high toxicity. Some Chinese herbal medicines have been reported to increase chemotherapy efficacy and reduce toxicity. In particular, Astragalus has been shown to have immunologic benefits by stimulating macrophage and natural killer cell activity and inhibiting T-helper cell type 2 cytokines. Many published studies have assessed the use of Astragalus and other Chinese herbal medicines in combination with chemotherapy. We sought to evaluate evidence from randomized trials that Astragalus-based Chinese herbal medicine combined with platinum-based chemotherapy (versus platinum-based chemotherapy alone) improves survival, increases tumor response, improves performance status, or reduces chemotherapy toxicity.
Methods: We searched CBM, MEDLINE, TCMLARS, EMBASE, Cochrane Library, and CCRCT databases for studies in any language. We grouped studies using the same herbal combinations for random-effects meta-analysis.
Results: Of 1,305 potentially relevant publications, 34 randomized studies representing 2,815 patients met inclusion criteria. Twelve studies (n = 940 patients) reported reduced risk of death at 12 months (risk ratio [RR] = 0.67; 95% CI, 0.52 to 0.87). Thirty studies (n = 2,472) reported improved tumor response data (RR = 1.34; 95% CI, 1.24 to 1.46). In subgroup analyses, Jin Fu Kang in two studies (n = 221 patients) reduced risk of death at 24 months (RR = 0.58; 95% CI, 0.49 to 0.68) and in three studies (n = 411) increased tumor response (RR = 1.76; 95% CI, 1.23 to 2.53). Ai Di injection (four studies; n = 257) stabilized or improved Karnofsky performance status (RR = 1.28; 95% CI, 1.12 to 1.46).
Conclusion: Astragalus-based Chinese herbal medicine may increase effectiveness of platinum-based chemotherapy when combined with chemotherapy. These results require confirmation with rigorously controlled trials.
Comment in
-
Important bias in the Astragalus meta-analysis.J Clin Oncol. 2006 Jul 1;24(19):3215-6; author reply 3216-7. doi: 10.1200/JCO.2006.06.2695. J Clin Oncol. 2006. PMID: 16809745 No abstract available.
Similar articles
-
Chinese herbal medicine and chemotherapy in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials.Integr Cancer Ther. 2005 Sep;4(3):219-29. doi: 10.1177/1534735405279927. Integr Cancer Ther. 2005. PMID: 16113029
-
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature.J Clin Oncol. 2005 May 1;23(13):2926-36. doi: 10.1200/JCO.2005.03.045. Epub 2005 Feb 22. J Clin Oncol. 2005. PMID: 15728229
-
A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.Lung Cancer. 2007 Sep;57(3):348-58. doi: 10.1016/j.lungcan.2007.03.014. Epub 2007 May 7. Lung Cancer. 2007. PMID: 17485133
-
Xiao-ai-ping injection adjunct with platinum-based chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.BMC Complement Med Ther. 2020 Jan 13;20(1):3. doi: 10.1186/s12906-019-2795-y. BMC Complement Med Ther. 2020. PMID: 32020869 Free PMC article.
-
The ALPI Trial: the Italian/European experience with adjuvant chemotherapy in resectable non-small lung cancer.Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5011s-5016s. doi: 10.1158/1078-0432.CCR-05-9009. Clin Cancer Res. 2005. PMID: 16000605 Review.
Cited by
-
Huisheng Oral Solution Adjunct With Platinum-Based Chemotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review.Front Pharmacol. 2020 Sep 8;11:476165. doi: 10.3389/fphar.2020.476165. eCollection 2020. Front Pharmacol. 2020. PMID: 33013377 Free PMC article.
-
Delisheng Injection (), a Chinese medicinal compound, enhanced the effect of cis-platinum on lung carcinoma cell line PGCL3.Chin J Integr Med. 2014 Apr;20(4):286-91. doi: 10.1007/s11655-013-1335-0. Epub 2013 Oct 23. Chin J Integr Med. 2014. PMID: 24155071
-
Danggui Buxue Decoction Sensitizes the Response of Non-Small-Cell Lung Cancer to Gemcitabine via Regulating Deoxycytidine Kinase and P-glycoprotein.Molecules. 2019 May 25;24(10):2011. doi: 10.3390/molecules24102011. Molecules. 2019. PMID: 31130654 Free PMC article.
-
Antrodia cinnamomea alleviates cisplatin-induced hepatotoxicity and enhances chemo-sensitivity of line-1 lung carcinoma xenografted in BALB/cByJ mice.Oncotarget. 2015 Sep 22;6(28):25741-54. doi: 10.18632/oncotarget.4348. Oncotarget. 2015. PMID: 26325335 Free PMC article.
-
Astragalus-containing Chinese herbal combinations for advanced non-small-cell lung cancer: a meta-analysis of 65 clinical trials enrolling 4751 patients.Lung Cancer (Auckl). 2010 Jul 8;1:85-100. doi: 10.2147/lctt.s7780. eCollection 2010. Lung Cancer (Auckl). 2010. PMID: 28210109 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous